Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
Menu
Articles
Author Correction
Autoimmune Diseases
Cardiovascular Conditions
Commentary
Correspondence
Dermatological Diseases
Endocrine Diseases
Gastrointestinal Conditions
General Indications
Hematology
Hereditary Genetic Disorders
Infectious Diseases
Methodology and Healthcare Policy
Nephrologic/Hepatologic Conditions
Neurological Diseases
Oncology
Ophthalmology
Other Conditions
Perspective
Psychological Conditions
Respiratory Diseases
Trauma Induced Conditions
Urological/Gynecological Diseases
All
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers
search
Sorry, something went wrong. Please try your search again.
×
Articles
Blog posts
RSS Feed
Enter the URL below into your favorite RSS reader.
https://jheor.org/feed
×
Urological/Gynecological Diseases
Vol. 5, Issue 2, 2018
January 09, 2018 EDT
Clinical and Economic Evaluation of Transdermal Oxybutynin in the Treatment of Overactive Bladder in Spain
Carlos Crespo
,
Pedro Blasco
,
Marcelo Guigini
,
Jordi Galván
,
oral muscarinic antagonists
mirabegron
persistence
cost–effectiveness
oxybutynin transdermal patch
idiopathic overactive bladder
Copyright Logo
ccby-4.0
•
https://doi.org/10.36469/9811
JHEOR
1.
Crespo C, Blasco P, Guigini M, Galván J. Clinical and Economic Evaluation of Transdermal Oxybutynin in the Treatment of Overactive Bladder in Spain.
JHEOR
. 2018;5(2):194-205.
doi:10.36469/9811
Save article as...
▾
PDF
XML
Citation (BibTeX)
View more stats